Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

Item
http://www.wikidata.org/entity/Q58411876
Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Platelet - leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk.Tissue factor, blood coagulation, and beyond: an overview.Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease miceTranslational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms.The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.How to manage essential thrombocythemia.Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.Are MPNs vascular diseases?Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond.Platelet-leukocyte mixed conjugates in patients with atrial fibrillation.Blood cell activation in myeloproliferative neoplasms.Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
P2860

Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

Item
http://www.wikidata.org/entity/Q58411876
description
im September 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 06 September 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2006
@uk
name
Inhibition of tissue factor ex ...... a new effect for an old drug?
@en
Inhibition of tissue factor ex ...... a new effect for an old drug?
@nl
type
label
Inhibition of tissue factor ex ...... a new effect for an old drug?
@en
Inhibition of tissue factor ex ...... a new effect for an old drug?
@nl
prefLabel
Inhibition of tissue factor ex ...... a new effect for an old drug?
@en
Inhibition of tissue factor ex ...... a new effect for an old drug?
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Inhibition of tissue factor ex ...... a new effect for an old drug?
@en
P2093
P2860
P304
P31
P356
10.1111/J.1538-7836.2006.02194.X
P433
P478
P50
P577
P698